Social Determinants of Health

The hidden risks of weight loss drugs

Erika Grotto
Published March 11, 2024 11:10 am | Updated April 30, 2024 4:48 pm

GLP-1 agonists, medications originally formulated to treat diabetes, have gained traction as prescription drugs for weight loss. On this episode, medical researcher and patient advocate Ragen Chastain discusses what healthcare providers should be sharing with their patients about the risks and efficacy of Wegovy and Zepbound.

About the Author

Erika Grotto

is a senior editor at HFMA and is based in Downers Grove, Ill.
See All Articles

Related Tags

Advertisements

googletag.cmd.push( function () { googletag.display( 'hfma-gpt-text1' ); } );
googletag.cmd.push( function () { googletag.display( 'hfma-gpt-text2' ); } );
googletag.cmd.push( function () { googletag.display( 'hfma-gpt-text3' ); } );
googletag.cmd.push( function () { googletag.display( 'hfma-gpt-text4' ); } );
googletag.cmd.push( function () { googletag.display( 'hfma-gpt-text5' ); } );
googletag.cmd.push( function () { googletag.display( 'hfma-gpt-text6' ); } );
googletag.cmd.push( function () { googletag.display( 'hfma-gpt-text7' ); } );
googletag.cmd.push( function () { googletag.display( 'hfma-gpt-leaderboard' ); } );
googletag.cmd.push( function () { googletag.display( 'hfma-gpt-cube1' ); } );
googletag.cmd.push( function () { googletag.display( 'hfma-gpt-cube2' ); } );

Recent Social Determinants of Health

News Briefs: A new fee is set for using the No Surprises Act arbitration portal

The big picture for healthcare in 2024, with Andrew Donahue

Recent updates and emerging best practices for ACOs in the Medicare Shared Savings Program

googletag.cmd.push( function () { googletag.display( 'hfma-gpt-cube3' ); } );
Recommended Articles

{{ loadingHeading }}

{{ loadingSubHeading }}

We’re having trouble logging you in.

For assistance, contact our Member Services Team.

Your session has expired.

Please reload the page and try again.